PFE vs. JNJ

In the year-to-date period, PFE achieves a -12.18% return, which is significantly lower than JNJ's 7.74% return. Over the past 10 years, PFE has underperformed JNJ with an annualized return of 0.48%, while JNJ has yielded a comparatively higher 7.32% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PFE Sharpe Ratio is -0.31, which is lower than the JNJ Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of PFE and JNJ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

PFE's dividend yield for the trailing twelve months is around 7.37%, more than JNJ's 3.21% yield.

The maximum PFE drawdown since its inception was -58.96%, which is greater than JNJ's maximum drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for PFE and JNJ. For additional features, visit the drawdowns tool.

The current volatility for Pfizer Inc. (PFE) is 10.22%, while Johnson & Johnson (JNJ) has a volatility of 10.88%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Pfizer Inc. and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.